undamentalytics Newsletter
Sign in

ARS Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, ARS Pharmaceuticals, Inc. had total assets of $328m, total liabilities of $213m and shareholders' equity of $114m. It held $41.3m in cash against $96.4m of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents602117151418
Receivables——082547
Inventory——0113131
Total current assets61278232334285212
Total assets61281233351328249
Accounts payable2211065
Deferred revenue (current)100111
Total current liabilities852233961
Long-term debt50—09697
Total debt80009697
Total liabilities179294213237
Shareholders' equity−3127323125711413
Non-controlling interests and other (assets − liabilities − equity)76—————
Shares outstanding30m—96m98m99m99m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: RCUS vs SPRYMESO vs SPRYSPRY vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ARS Pharmaceuticals, Inc.